Global Mice Model Market to Reach $2.6 Billion by 2030

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet.

| Source: ReportLinker ReportLinker

New York, March 28, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Mice Model Industry" - https://www.reportlinker.com/p05957356/?utm_source=GNW
Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Mice Model Market to Reach $2.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Mice Model estimated at US$1.8 Billion in the year 2022, is projected to reach a revised size of US$2.6 Billion by 2030, growing at aCAGR of 5.3% over the period 2022-2030. CRISPR / CAS9, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$976.7 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Microinjection segment is readjusted to a revised 4.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $468.2 Million, While China is Forecast to Grow at 8.2% CAGR

The Mice Model market in the U.S. is estimated at US$468.2 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$603.1 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 4.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Select Competitors (Total 46 Featured)
- Charles River Laboratories International, Inc.
- Envigo, Inc.
- Genoway S.A.
- Harbour Antibodies BV
- Horizon Discovery Group PLC
- inGenious Targeting Laboratory, Inc.
- Janvier Labs
- Laboratory Corporation of America Holdings (LabCorp)
- Taconic Biosciences, Inc.
- The Jackson Laboratory
- Trans Genic, Inc.


Read the full report: https://www.reportlinker.com/p05957356/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Mice Model - Global Key Competitors Percentage Market Share in
2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for Mice
Model by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2022 through 2030 and % CAGR

Table 2: World Historic Review for Mice Model by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 3: World 16-Year Perspective for Mice Model by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets for Years 2014, 2023 & 2030

Table 4: World Recent Past, Current & Future Analysis for
Microinjection by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 5: World Historic Review for Microinjection by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 6: World 16-Year Perspective for Microinjection by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 7: World Recent Past, Current & Future Analysis for
Embryonic Stem Cell Injection by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

Table 8: World Historic Review for Embryonic Stem Cell
Injection by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2014 through 2021 and % CAGR

Table 9: World 16-Year Perspective for Embryonic Stem Cell
Injection by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 10: World Recent Past, Current & Future Analysis for
Nuclear Transfer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 11: World Historic Review for Nuclear Transfer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 12: World 16-Year Perspective for Nuclear Transfer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 13: World Recent Past, Current & Future Analysis for
Other Technologies by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 14: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 15: World 16-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 16: World Recent Past, Current & Future Analysis for
Breeding by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR

Table 17: World Historic Review for Breeding by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 18: World 16-Year Perspective for Breeding by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 19: World Recent Past, Current & Future Analysis for
Cryopreservation by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 20: World Historic Review for Cryopreservation by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 21: World 16-Year Perspective for Cryopreservation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 22: World Recent Past, Current & Future Analysis for
Genetic Testing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 23: World Historic Review for Genetic Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 24: World 16-Year Perspective for Genetic Testing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 25: World Recent Past, Current & Future Analysis for
Other Services by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 26: World Historic Review for Other Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 27: World 16-Year Perspective for Other Services by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 28: World Recent Past, Current & Future Analysis for
Other Therapeutic Areas by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR

Table 29: World Historic Review for Other Therapeutic Areas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 30: World 16-Year Perspective for Other Therapeutic Areas
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 31: World Mice Model Market Analysis of Annual Sales in
US$ Thousand for Years 2014 through 2030

Table 32: World Recent Past, Current & Future Analysis for
CRISPR / CAS9 by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR

Table 33: World Historic Review for CRISPR / CAS9 by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 34: World 16-Year Perspective for CRISPR / CAS9 by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 35: World Recent Past, Current & Future Analysis for
Quarantine by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR

Table 36: World Historic Review for Quarantine by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 37: World 16-Year Perspective for Quarantine by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 38: World Recent Past, Current & Future Analysis for
Model-In Licensing by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 39: World Historic Review for Model-In Licensing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 40: World 16-Year Perspective for Model-In Licensing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

Table 41: World Recent Past, Current & Future Analysis for
Oncology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR

Table 42: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 43: World 16-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 44: World Recent Past, Current & Future Analysis for
Central Nervous System (CNS) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2022 through 2030 and % CAGR

Table 45: World Historic Review for Central Nervous System
(CNS) by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 46: World 16-Year Perspective for Central Nervous System
(CNS) by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2014, 2023 &
2030

Table 47: World Recent Past, Current & Future Analysis for
Immunology & Inflammation by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Thousand for Years 2022 through 2030 and % CAGR

Table 48: World Historic Review for Immunology & Inflammation
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 49: World 16-Year Perspective for Immunology &
Inflammation by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2014, 2023 & 2030

Table 50: World Recent Past, Current & Future Analysis for
Diabetes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2022 through 2030 and % CAGR

Table 51: World Historic Review for Diabetes by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2014 through 2021 and
% CAGR

Table 52: World 16-Year Perspective for Diabetes by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2014, 2023 & 2030

Table 53: World Recent Past, Current & Future Analysis for
Cardiovascular by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2022 through 2030 and % CAGR

Table 54: World Historic Review for Cardiovascular by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2014 through 2021 and % CAGR

Table 55: World 16-Year Perspective for Cardiovascular by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

UNITED STATES
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in the United States for 2023 (E)
Table 56: USA Recent Past, Current & Future Analysis for Mice
Model by Technology - CRISPR / CAS9, Microinjection, Embryonic
Stem Cell Injection, Nuclear Transfer and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 57: USA Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 58: USA 16-Year Perspective for Mice Model by Technology -
Percentage Breakdown of Value Sales for CRISPR / CAS9,
Microinjection, Embryonic Stem Cell Injection, Nuclear Transfer
and Other Technologies for the Years 2014, 2023 & 2030

Table 59: USA Recent Past, Current & Future Analysis for Mice
Model by Service - Breeding, Cryopreservation, Genetic Testing,
Quarantine, Model-In Licensing and Other Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 60: USA Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 61: USA 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 62: USA Recent Past, Current & Future Analysis for Mice
Model by Therapeutic Area - Oncology, Central Nervous System
(CNS), Immunology & Inflammation, Diabetes, Cardiovascular and
Other Therapeutic Areas - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2022 through 2030 and % CAGR

Table 63: USA Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 64: USA 16-Year Perspective for Mice Model by Therapeutic
Area - Percentage Breakdown of Value Sales for Oncology,
Central Nervous System (CNS), Immunology & Inflammation,
Diabetes, Cardiovascular and Other Therapeutic Areas for the
Years 2014, 2023 & 2030

CANADA
Table 65: Canada Recent Past, Current & Future Analysis for
Mice Model by Technology - CRISPR / CAS9, Microinjection,
Embryonic Stem Cell Injection, Nuclear Transfer and Other
Technologies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR

Table 66: Canada Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 67: Canada 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 68: Canada Recent Past, Current & Future Analysis for
Mice Model by Service - Breeding, Cryopreservation, Genetic
Testing, Quarantine, Model-In Licensing and Other Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 69: Canada Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 70: Canada 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 71: Canada Recent Past, Current & Future Analysis for
Mice Model by Therapeutic Area - Oncology, Central Nervous
System (CNS), Immunology & Inflammation, Diabetes,
Cardiovascular and Other Therapeutic Areas - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 72: Canada Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 73: Canada 16-Year Perspective for Mice Model by
Therapeutic Area - Percentage Breakdown of Value Sales for
Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas for the Years 2014, 2023 & 2030

JAPAN
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Japan for 2023 (E)
Table 74: Japan Recent Past, Current & Future Analysis for Mice
Model by Technology - CRISPR / CAS9, Microinjection, Embryonic
Stem Cell Injection, Nuclear Transfer and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 75: Japan Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 76: Japan 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 77: Japan Recent Past, Current & Future Analysis for Mice
Model by Service - Breeding, Cryopreservation, Genetic Testing,
Quarantine, Model-In Licensing and Other Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 78: Japan Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 79: Japan 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 80: Japan Recent Past, Current & Future Analysis for Mice
Model by Therapeutic Area - Oncology, Central Nervous System
(CNS), Immunology & Inflammation, Diabetes, Cardiovascular and
Other Therapeutic Areas - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2022 through 2030 and % CAGR

Table 81: Japan Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 82: Japan 16-Year Perspective for Mice Model by
Therapeutic Area - Percentage Breakdown of Value Sales for
Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas for the Years 2014, 2023 & 2030

CHINA
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in China for 2023 (E)
Table 83: China Recent Past, Current & Future Analysis for Mice
Model by Technology - CRISPR / CAS9, Microinjection, Embryonic
Stem Cell Injection, Nuclear Transfer and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 84: China Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 85: China 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 86: China Recent Past, Current & Future Analysis for Mice
Model by Service - Breeding, Cryopreservation, Genetic Testing,
Quarantine, Model-In Licensing and Other Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 87: China Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 88: China 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 89: China Recent Past, Current & Future Analysis for Mice
Model by Therapeutic Area - Oncology, Central Nervous System
(CNS), Immunology & Inflammation, Diabetes, Cardiovascular and
Other Therapeutic Areas - Independent Analysis of Annual Sales
in US$ Thousand for the Years 2022 through 2030 and % CAGR

Table 90: China Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 91: China 16-Year Perspective for Mice Model by
Therapeutic Area - Percentage Breakdown of Value Sales for
Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas for the Years 2014, 2023 & 2030

EUROPE
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Europe for 2023 (E)
Table 92: Europe Recent Past, Current & Future Analysis for
Mice Model by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2022 through 2030 and
% CAGR

Table 93: Europe Historic Review for Mice Model by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 94: Europe 16-Year Perspective for Mice Model by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2014, 2023 & 2030

Table 95: Europe Recent Past, Current & Future Analysis for
Mice Model by Technology - CRISPR / CAS9, Microinjection,
Embryonic Stem Cell Injection, Nuclear Transfer and Other
Technologies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR

Table 96: Europe Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 97: Europe 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 98: Europe Recent Past, Current & Future Analysis for
Mice Model by Service - Breeding, Cryopreservation, Genetic
Testing, Quarantine, Model-In Licensing and Other Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 99: Europe Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 100: Europe 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 101: Europe Recent Past, Current & Future Analysis for
Mice Model by Therapeutic Area - Oncology, Central Nervous
System (CNS), Immunology & Inflammation, Diabetes,
Cardiovascular and Other Therapeutic Areas - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 102: Europe Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 103: Europe 16-Year Perspective for Mice Model by
Therapeutic Area - Percentage Breakdown of Value Sales for
Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas for the Years 2014, 2023 & 2030

FRANCE
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in France for 2023 (E)
Table 104: France Recent Past, Current & Future Analysis for
Mice Model by Technology - CRISPR / CAS9, Microinjection,
Embryonic Stem Cell Injection, Nuclear Transfer and Other
Technologies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR

Table 105: France Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 106: France 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 107: France Recent Past, Current & Future Analysis for
Mice Model by Service - Breeding, Cryopreservation, Genetic
Testing, Quarantine, Model-In Licensing and Other Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2022 through 2030 and % CAGR

Table 108: France Historic Review for Mice Model by Service -
Breeding, Cryopreservation, Genetic Testing, Quarantine,
Model-In Licensing and Other Services Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 109: France 16-Year Perspective for Mice Model by Service -
Percentage Breakdown of Value Sales for Breeding,
Cryopreservation, Genetic Testing, Quarantine, Model-In
Licensing and Other Services for the Years 2014, 2023 & 2030

Table 110: France Recent Past, Current & Future Analysis for
Mice Model by Therapeutic Area - Oncology, Central Nervous
System (CNS), Immunology & Inflammation, Diabetes,
Cardiovascular and Other Therapeutic Areas - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2022
through 2030 and % CAGR

Table 111: France Historic Review for Mice Model by Therapeutic
Area - Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2014 through 2021 and % CAGR

Table 112: France 16-Year Perspective for Mice Model by
Therapeutic Area - Percentage Breakdown of Value Sales for
Oncology, Central Nervous System (CNS), Immunology &
Inflammation, Diabetes, Cardiovascular and Other Therapeutic
Areas for the Years 2014, 2023 & 2030

GERMANY
Mice Model Market Presence - Strong/Active/Niche/Trivial - Key
Competitors in Germany for 2023 (E)
Table 113: Germany Recent Past, Current & Future Analysis for
Mice Model by Technology - CRISPR / CAS9, Microinjection,
Embryonic Stem Cell Injection, Nuclear Transfer and Other
Technologies - Independent Analysis of Annual Sales in US$
Thousand for the Years 2022 through 2030 and % CAGR

Table 114: Germany Historic Review for Mice Model by Technology -
CRISPR / CAS9, Microinjection, Embryonic Stem Cell Injection,
Nuclear Transfer and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2014 through
2021 and % CAGR

Table 115: Germany 16-Year Perspective for Mice Model by
Technology - Percentage Breakdown of Value Sales for CRISPR /
CAS9, Microinjection, Embryonic Stem Cell Injection, Nuclear
Transfer and Other Technologies for the Years 2014, 2023 & 2030

Table 116: Germany Recent Past, Current & Future Analysis for

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05957356/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

 

            











    

        

        
Contact Data